[Federal Register Volume 88, Number 96 (Thursday, May 18, 2023)]
[Notices]
[Pages 31760-31762]
[FR Doc No: 2023-10603]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2017-N-5925]

21st Century Cures Act: Annual Compilation of Notices of Updates
From the Susceptibility Test Interpretive Criteria Web Page, 2021 and
2022 Updates; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is
announcing the availability of the Agency's annual compilation of
notices of updates to the Agency's Susceptibility Test Interpretive
Criteria web page with updates made in 2021 and 2022. The Agency
established the Susceptibility Test Interpretive Criteria web page on
December 13, 2017, and since establishment has provided updates to both
the format of the web pages and to the susceptibility test interpretive
criteria identified and recognized by FDA on the web pages. FDA is
publishing this notice in accordance with procedures established by the
21st Century Cures Act (Cures Act).

DATES: This notice is published in the Federal Register on May 18,
2023.

ADDRESSES: You may submit either electronic or written comments and
information as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2017-N-5925 for ``Susceptibility Test Interpretive Criteria
Recognized and Listed on the Susceptibility Test Interpretive web page;
Request for Comments.'' Received comments will be placed in the docket
and, except for those submitted as ``Confidential Submissions,''
publicly viewable at https://www.regulations.gov or at the Dockets
Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-
402-7500.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://

www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852,<PHONE_NUMBER>.

FOR FURTHER INFORMATION CONTACT: Deborah (Wang) Kim, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, Rm. 6349, Silver Spring, MD 20993-0002, 301-
796-9053, [email protected].

SUPPLEMENTARY INFORMATION:

I. Background

    Section 511A of the Federal Food, Drug, and Cosmetic Act (the FD&C
Act) (21 U.S.C. 360a-2), as added by section 3044 of the Cures Act
(Pub. L. 114-255), was signed into law on December 13, 2016. This
provision clarified FDA's authority to identify and efficiently update
susceptibility test interpretive criteria, including through the
recognition by FDA of standards established by standards development
organizations (SDOs). It also clarified that sponsors of antimicrobial
susceptibility testing devices may rely upon listed susceptibility test
interpretive criteria to support premarket authorization of their
devices, provided they meet certain conditions, which allows for a more
streamlined process for incorporating up-to-date information into such
devices.
    In the Federal Register notice of December 13, 2017 (82 FR 58617),
FDA announced the establishment of the Susceptibility Test Interpretive
Criteria web page. This web page recognizes susceptibility test
interpretive criteria established by an SDO that fulfills the
requirements under section 511A(b)(2)(A) of the FD&C Act; identifies
when FDA does not recognize, in whole or in part, susceptibility test
interpretive criteria established by an SDO; and lists susceptibility
test interpretive criteria identified by FDA outside the SDO process.
The susceptibility test interpretive criteria listed by FDA on the
Susceptibility Test Interpretive Criteria web page is deemed to be
recognized as a standard under section 514(c)(1) of the FD&C Act (21
U.S.C. 360d(c)(1)). The Susceptibility Test Interpretive Criteria web
page can be found at https://www.fda.gov/STIC.
    On March 1, 2018, FDA published a notice in the Federal Register
(83 FR 8883) requesting comments on FDA's initial susceptibility test
interpretive criteria recognition and listing determinations on the
Susceptibility Test Interpretive Criteria web page (https://www.federalregister.gov/documents/2018/03/01/2018-04175/susceptibility-test-interpretive-criteria-recognized-and-listed-on-the-susceptibility-test). FDA may consider information provided by interested third
parties as a basis for evaluating new or updated interpretive criteria
standards (section 511A(c)(2)(B) of the FD&C Act); third parties should
submit any information they wish to convey to the Agency to Docket No.
FDA-2017-N-5925. If comments are received, FDA will review those
comments and will make, as appropriate, updates to the recognized
standards or susceptibility test interpretive criteria.
    At least every 6 months after the establishment of the
Susceptibility Test Interpretive Criteria web page, FDA is required, as
appropriate to: (1) publish on that web page a notice recognizing new
or updated susceptibility test interpretive criteria standards, or
recognizing or declining to recognize parts of standards; (2) withdraw
recognition of susceptibility test interpretive criteria standards, or
parts of standards; and (3) make any other necessary updates to the
lists published on the Susceptibility Test Interpretive Criteria web
page (section 511A(c)(1)(A) of the FD&C Act). FDA has provided notices
of updates on the Susceptibility Test Interpretive Criteria web page,
which can be found here: https://www.fda.gov/drugs/development-resources/notice-updates. Interested parties may also sign up to
receive emails informing them of these updates as they occur by using
the link provided either on the main Susceptibility Test Interpretive
Criteria web page (https://www.fda.gov/STIC) or on the updates page.
    Once a year, FDA is required to compile the new notices published
on the Susceptibility Test Interpretive Criteria web page, publish them
in the Federal Register, and provide for public comment (see section
511A(c)(3) of the FD&C Act). This Federal Register notice satisfies
that requirement. If comments are received, FDA will review them and
make updates to the recognized standards or susceptibility test
interpretive criteria as needed.

II. Annual Compilation of Notices, 2021: Web Page

                       Table 1--Notices of Updates to Recognized or Updated Susceptibility Test Interpretive Criteria by Drug \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
                Drug                  Route of administration                    Action taken                      Therapeutic category        Date
--------------------------------------------------------------------------------------------------------------------------------------------------------
Azithromycin........................  Oral, Injection........  For Neisseria gonorrhoeae, FDA has reviewed       Antibacterial..........        10/14/21
                                                                susceptibility test interpretive criteria and
                                                                concludes no changes are needed at this time.
                                                                (Rationale available at https://www.fda.gov/drugs/development-resources/rationale-fdas-position-azithromycin-susceptible-only-breakpoint-neisseria-gonorrhoeae).
Cefazolin...........................  Injection..............  For Enterobacterales, FDA has reviewed            Antibacterial..........        10/14/21
                                                                susceptibility test interpretive criteria and
                                                                the updated standard is recognized. (Rationale
                                                                available at https://www.fda.gov/drugs/development-resources/.
                                                                rationale-fdas-position-cefazolin-breakpoints-
                                                                enterobacterales).
Cefiderocol.........................  Injection..............  FDA recognizes M100 MIC standard for              Antibacterial..........        10/14/21
                                                                Enterobacteriaceae.
Ceftolozane; tazobactam.............  Injection..............  FDA recognizes M100 standard for Haemophilus      Antibacterial..........        10/14/21
                                                                influenzae.
Colistimethate......................  Injection..............  FDA does not recognize M100 standard for          Antibacterial..........        10/14/21
                                                                Enterobacteriaceae.
Imipenem/cilastatin/relebactam......  Injection..............  FDA recognizes M100 standard for                  Antibacterial..........        10/14/21
                                                                Enterobacteriaceae, Pseudomonas aeruginosa, and
                                                                anaerobes.
Lefamulin...........................  Oral, Injection........  FDA recognizes M100 standard for Staphylococcus   Antibacterial..........        10/14/21
                                                                aureus, Streptococcus pneumoniae, and
                                                                Haemophilus influenzae.
Polymyxin B.........................  Injection..............  FDA does not recognize M100 standard for          Antibacterial..........        10/14/21
                                                                Enterobacteriaceae and Pseudomonas aeruginosa.

Telithromycin.......................  Oral...................  FDA has removed telithromycin susceptibility      Antibacterial..........        10/14/21
                                                                test interpretive criteria as the drug is no
                                                                longer approved in any application under
                                                                section 505 of the FD&C Act (21 U.S.C. 355)
                                                                (see 84 FR 47309).
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ M100 standard in the table refers to Clinical and Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility
  Testing, 31st ed. CLSI supplement M100; 2021.

III. Annual Compilation of Notices, 2022: Susceptibility Test
Interpretive Criteria Web Page

A. Updates to Standards Recognition

    As of May 18, 2022, the following standards are no longer
recognized: ``Clinical and Laboratory Standards Institute (CLSI).
Performance Standards for Antimicrobial Susceptibility Testing. 31st
ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards
Institute; 2021.''
    As of May 18, 2022, with certain exceptions, FDA recognizes the
standards published in: ``Clinical and Laboratory Standards Institute
(CLSI). Performance Standards for Antimicrobial Susceptibility Testing.
32nd ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory
Standards Institute; 2022.''

B. Updates by Drug

                       Table 2--Notices of Updates to Recognized or Updated Susceptibility Test Interpretive Criteria by Drug \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
                Drug                  Route of administration                    Action taken                      Therapeutic category        Date
--------------------------------------------------------------------------------------------------------------------------------------------------------
Amoxicillin and clavulanate.........  Oral...................  FDA does not recognize M100 standard and          Antibacterial..........         5/17/22
                                                                provides susceptibility test interpretive
                                                                criteria for Haemophilus influenzae.
Cefadroxil..........................  Oral...................  FDA removed the statement ``Susceptibility of     Antibacterial..........         4/27/22
                                                                Enterobacteriaceae to cefadroxil may be deduced
                                                                from testing cefazolin.'' (Rationale available
                                                                at https://www.fda.gov/drugs/development-resources/ resources/.
                                                                rationale-fdas-position-cefadroxil.)...........
Cefazolin...........................  Injection..............  FDA does not recognize M100 standard for          Antibacterial..........        10/20/22
                                                                cefazolin as a surrogate to predict
                                                                susceptibility of oral cephalosporins when used
                                                                for the treatment of uncomplicated urinary
                                                                tract infections caused by Escherichia coli,
                                                                Klebsiella pneumoniae and Proteus mirabilis.
                                                                (Rationale available at https://www.fda.gov/drugs/development-.
                                                                resources/rationale-fdas-position-use-cefazolin-
                                                                breakpoints-surrogate-determining-breakpoints-
                                                                oral.).
Cefoxitin...........................  Injection..............  FDA recognizes M100 standard for Staphylococcus   Antibacterial..........         10/4/22
                                                                aureus complex and Staphylococcus lugdunensis.
                                                                FDA recognizes M100 disk diffusion standard for
                                                                Staphylococcus epidermidis and other
                                                                Staphylococci spp.
Ceftolozane and tazobactam..........  Injection..............  FDA recognizes M100 disk diffusion standard for   Antibacterial..........         5/17/22
                                                                Enterobacterales.
Lefamulin...........................  Oral, Injection........  FDA does not recognize M100 disk diffusion        Antibacterial..........         5/17/22
                                                                standard and provides susceptibility test
                                                                interpretive criteria for Streptococcus
                                                                pneumoniae and Haemophilus influenzae.
Oxacillin...........................  Injection..............  FDA concurs with the revised CLSI susceptibility  Antibacterial..........         10/4/22
                                                                test interpretive criteria for Staphylococcus
                                                                by species level. (Rationale available at
                                                                https://www.fda.gov/drugs/development-resources/rationale-fdas-position-oxacillin-breakpoints-staphylococcus staphylococcus). FDA references Cefoxitin
                                                                susceptibility test interpretive for
                                                                Staphylococcus spp. as a surrogate test.
Piperacillin and tazobactam.........  Injection..............  FDA does not recognize M100 standard for          Antibacterial..........         5/17/22
                                                                Enterobacterales.
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ M100 standard in the table refers to CLSI Performance Standards for Antimicrobial Susceptibility Testing, 32nd ed. CLSI supplement M100; 2022.

    Dated: May 15, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-10603 Filed 5-17-23; 8:45 am]
BILLING CODE 4164-01-P


[Federal Register Volume 81, Number 115 (Wednesday, June 15, 2016)]
[Notices]
[Pages 39060-39061]
[FR Doc No: 2016-14154]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

[Docket No. USCG-2016-0301]

Navigation Safety Advisory Council; Vacancies

AGENCY: Coast Guard, Department of Homeland Security.

ACTION: Request for applications.

-----------------------------------------------------------------------

SUMMARY: The Coast Guard seeks applications for membership on the
Navigation Safety Advisory Council. The Navigation Safety Advisory
Council provides advice and recommendations to the Secretary of
Homeland Security, through the Commandant of the U.S. Coast Guard, on
matters relating to maritime collisions, rammings, and groundings;
Inland Rules of the Road; International Rules of the Road; navigation
regulations and equipment, routing measures, marine information, diving
safety, and aids to navigation systems.

DATES: Completed applications should reach the Coast Guard on or before
August 15, 2016.

ADDRESSES: Applicants should send a cover letter expressing interest in
an appointment to the Navigation Safety Advisory Council that
identifies which membership category the applicant is applying under,
along with a resume detailing the applicant's experience via one of the
following methods:
     By Email: to<EMAIL_ADDRESS>(preferred);
     By Mail: Commandant (CG-NAV-2)/NAVSAC Attn: Mr. George
Detweiler, Alternate Designated Federal Officer, Commandant (CG-NAV-2),
U.S. Coast Guard, 2703 Martin Luther King Avenue SE., STOP 7418,
Washington, DC 20593-7418; or
     By Fax:<PHONE_NUMBER>.

FOR FURTHER INFORMATION CONTACT: Mr. George Detweiler, the Navigation
Safety Advisory Council Alternate Designated Federal Officer, telephone
202-372-1566, fax<PHONE_NUMBER>, or email<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION: The Navigation Safety Advisory Council is a
federal advisory committee authorized by 33 U.S.C. 2073 and chartered
under the provisions of the Federal Advisory Committee Act, (Title 5
U.S.C. Appendix).
    The Navigation Safety Advisory Council provides advice and
recommendations to the Secretary of Homeland Security, through the
Commandant of the U.S. Coast Guard, on matters relating to maritime
collisions, rammings, and groundings; Inland Rules of the Road;
International Rules of the Road; navigation regulations and equipment,
routing measures, marine information, diving safety, and aids to
navigation systems.
    The Navigation Safety Advisory Council is expected to meet at least
twice each year. All members serve at their own expense and receive no
salary from the Federal Government, although travel reimbursement and
per diem may be provided for called meetings.
    The Coast Guard will consider applications for seven positions that
will be vacant on November 4, 2016, in the following membership
categories only:
    a. Commercial vessel owners and operators;
    b. Professional mariners;
    c. Recreational boaters;
    d. Recreational Boating Industry; and
    e. State agencies responsible for vessel or port safety.
    To be eligible, applicants should have experience in one of the
categories listed above. Members serve terms of office of up to three
(3) years. Members are limited to serving no more than two (2)
consecutive terms. In the event the Navigation Safety Advisory Council
terminates, all appointments to the Council terminate.
    Registered lobbyists are not eligible to serve on federal advisory
committees in an individual capacity. See ``Revised Guidance on
Appointment of Lobbyists to Federal Advisory Committees, Boards and
Commissions'' (79 FR 47482, August 13, 2014). Registered lobbyists are
lobbyists required to comply with provisions contained in 2 U.S.C.
1605.
    The Department of Homeland Security does not discriminate in
selecting Council members on the basis of race, color, religion, sex,
national origin, political affiliation, sexual orientation, gender
identity, marital status, disability and genetic information, age,
membership in an employee organization, or any other non-merit factor.
The Department of Homeland Security strives to achieve a widely diverse
candidate pool for all of its recruitment actions.
    If you are interested in applying to become a member of the
Council, submit your complete application package to Mr. George
Detweiler, the Navigation Safety Advisory Council Alternate Designated
Federal Officer via one of the transmittal methods in the ADDRESSES
section by the deadline in the DATES section of this notice.
    All email submittals will receive email receipt confirmation.

    Dated: June 10, 2016.
David C. Barata,
Captain, U.S. Coast Guard, Acting Director, Marine Transportation
Systems.
[FR Doc. 2016-14154 Filed 6-14-16; 8:45 am]
BILLING CODE 9110-04-P


[Federal Register Volume 79, Number 85 (Friday, May 2, 2014)]
[Notices]
[Pages 25173-25174]
[FR Doc No: 2014-10056]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

[Summary Notice No. PE-2014-20]

Petition for Exemption; Summary of Petition Received

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice of petition for exemption received.

-----------------------------------------------------------------------

SUMMARY: This notice contains a summary of a petition seeking relief
from specified requirements of 14 CFR. The purpose of this notice is to
improve the public's awareness of, and participation in, this aspect of
FAA's regulatory activities. Neither publication of this notice nor the
inclusion or omission of information in the summary is intended to
affect the legal status of the petition or its final disposition.

DATES: Comments on this petition must identify the petition docket
number and must be received on or before May 22, 2014.

ADDRESSES: You may send comments identified by Docket Number FAA-2014-
0107 using any of the following methods:
     Government-wide rulemaking Web site: Go to http://www.regulations.gov and follow the instructions for sending your
comments electronically.
     Mail: Send comments to the Docket Management Facility;
U.S. Department

of Transportation, 1200 New Jersey Avenue SE., West Building Ground
Floor, Room W12-140, Washington, DC 20590.
     Fax: Fax comments to the Docket Management Facility at
202-493-2251.
     Hand Delivery: Bring comments to the Docket Management
Facility in Room W12-140 of the West Building Ground Floor at 1200 New
Jersey Avenue SE., Washington, DC, between 9 a.m. and 5 p.m., Monday
through Friday, except Federal holidays.
    Privacy: We will post all comments we receive, without change, to
http://www.regulations.gov, including any personal information you
provide. Using the search function of our docket Web site, anyone can
find and read the comments received into any of our dockets, including
the name of the individual sending the comment (or signing the comment
for an association, business, labor union, etc.). You may review DOT's
complete Privacy Act Statement in the Federal Register published on
April 11, 2000 (65 FR 19477-78).
    Docket: To read background documents or comments received, go to
http://www.regulations.gov at any time or to the Docket Management
Facility in Room W12-140 of the West Building Ground Floor at 1200 New
Jersey Avenue SE., Washington, DC, between 9 a.m. and 5 p.m., Monday
through Friday, except Federal holidays.

FOR FURTHER INFORMATION CONTACT: Nia Daniels<PHONE_NUMBER>, Office of
Rulemaking, Federal Aviation Administration, 800 Independence Avenue
SW., Washington, DC 20591.
    This notice is published pursuant to 14 CFR 11.85.

    Issued in Washington, DC, on April 28, 2014.
Lirio Liu,
Director, Office of Rulemaking.

Petition for Exemption

    Docket No.: FAA-2014-0107.
    Petitioner: Tatonduk Outfitters Limited d/b/a Everts Air Cargo.
    Section of 14 CFR Affected: 14 CFR 121.436.
    Description of Relief Sought: Tatonduk Outfitters Limited d/b/a
Everts Air Cargo is seeking relief from 14 CFR 121.436 to operate with
a second-in-command pilot holding a second-in-command type rating
issued in accordance with Sec.  61.55, for cargo operations conducted
solely in the state of Alaska.

[FR Doc. 2014-10056 Filed 5-1-14; 8:45 am]
BILLING CODE 4910-13-P


[Federal Register Volume 79, Number 165 (Tuesday, August 26, 2014)]
[Proposed Rules]
[Pages 50857-50859]
[FR Doc No: 2014-20260]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. FAA-2014-0586; Directorate Identifier 2013-NM-255-AD]
RIN 2120-AA64

Airworthiness Directives; Empresa Brasileira de Aeronautica S.A.
(Embraer) Airplanes

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice of proposed rulemaking (NPRM).

-----------------------------------------------------------------------

SUMMARY: We propose to adopt a new airworthiness directive (AD) for all
Empresa Brasileira de Aeronautica S.A. (Embraer) Model EMB-135BJ
airplanes. This proposed AD was prompted by a determination that more
restrictive fuel limitations are needed. This proposed AD would require
revising the maintenance or inspection program to incorporate new
compliance times and fuel limitations. We are proposing this AD to
detect and correct fatigue cracking of various structural elements and
prevent ignition sources in the fuel system.

DATES: We must receive comments on this proposed AD by October 10,
2014.

ADDRESSES: You may send comments by any of the following methods:
     Federal eRulemaking Portal: Go to http://www.regulations.gov. Follow the instructions for submitting comments.
     Fax:<PHONE_NUMBER>.
     Mail: U.S. Department of Transportation, Docket
Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New
Jersey Avenue SE., Washington, DC 20590.
     Hand Delivery: U.S. Department of Transportation, Docket
Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New
Jersey Avenue SE., Washington, DC, between 9 a.m. and 5 p.m., Monday
through Friday, except Federal holidays.
    For service information identified in this proposed AD, contact
Empresa Brasileira de Aeronautica S.A. (Embraer), Technical
Publications Section (PC 060), Av. Brigadeiro Faria Lima, 2170--Putim--
12227-901 S[atilde]o Jose dos Campos--SP--Brasil; telephone +55 12
3927-5852 or +55 12 3309-0732; fax +55 12 3927-7546; email
<EMAIL_ADDRESS>Internet http://www.flyembraer.com. You may
view this referenced service information at the FAA, Transport Airplane
Directorate, 1601 Lind Avenue SW., Renton, WA. For information on the
availability of this material at the FAA, call<PHONE_NUMBER>.

Examining the AD Docket

    You may examine the AD docket on the Internet at http://www.regulations.gov by searching for and locating Docket No. FAA-2014-
0586; or in person at the Docket Management Facility between 9 a.m. and
5 p.m., Monday through Friday, except Federal holidays. The AD docket
contains this proposed AD, the regulatory evaluation, any comments
received, and other information. The street address for the Docket
Operations office (telephone<PHONE_NUMBER>) is in the ADDRESSES
section. Comments will be available in the AD docket shortly after
receipt.

FOR FURTHER INFORMATION CONTACT: Todd Thompson, Aerospace Engineer,
International Branch, ANM-116, Transport Airplane Directorate, FAA,
1601 Lind Avenue SW., Renton, WA 98057-3356; telephone<PHONE_NUMBER>;
fax<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

Comments Invited

    We invite you to send any written relevant data, views, or
arguments about this proposed AD. Send your comments to an address
listed under the ADDRESSES section. Include ``Docket No. FAA-2014-0586;
Directorate Identifier 2013-NM-255-AD'' at the beginning of your
comments. We specifically invite comments on the overall regulatory,
economic, environmental, and energy aspects of this proposed AD. We
will consider all comments received by the closing date and may amend
this proposed AD based on those comments.
    We will post all comments we receive, without change, to http://www.regulations.gov, including any personal information you provide. We
will also post a report summarizing each substantive verbal contact we
receive about this proposed AD.

Discussion

    The Ag[ecirc]ncia Nacional De Avia[ccedil][atilde]o Civil (ANAC),
which is the aviation authority for Brazil, has issued Brazilian
Airworthiness Directive 2013-12-02, effective December 27, 2013
(referred to after this as the Mandatory Continuing Airworthiness
Information, or ``the MCAI''), to correct an unsafe condition for all
Empresa Brasileira de Aeronautica S.A. (Embraer) Model EMB-135BJ
airplanes. The MCAI states:

    This [Brazilian] AD was prompted by a new revision to the
Airworthiness Limitations Requirements of the Maintenance Planning
Guide (MPG-1483). We are issuing this [Brazilian] AD to allow timely
detection and correction of fatigue cracking of various structural
elements, and to allow the necessary preclusion of ignition sources
in the fuel system.

    Required actions include revising the maintenance or inspection
program, as applicable, to incorporate new compliance times and fuel
limitations. You may examine the MCAI in the AD docket on the Internet
at http://www.regulations.gov by searching for and locating Docket No.
FAA-2014-0586.

Relevant Service Information

    Embraer has issued the following service information. The actions
described in this service information are intended to correct the
unsafe condition identified in the MCAI.
     Temporary Revision (TR) 8-1, dated October 26, 2012, to
the Embraer Legacy BJ Maintenance Planning Guide (MPG), MPG-1483.
     TR 8-2, dated December 5, 2012, to the Embraer Legacy BJ
MPG, MPG-1483.
     TR 8-3, dated April 8, 2013, to the Embraer Legacy BJ MPG,
MPG-1483.

FAA's Determination and Requirements of This Proposed AD

    This product has been approved by the aviation authority of another
country, and is approved for operation in the United States. Pursuant
to our bilateral agreement with the State of

Design Authority, we have been notified of the unsafe condition
described in the MCAI and service information referenced above. We are
proposing this AD because we evaluated all pertinent information and
determined an unsafe condition exists and is likely to exist or develop
on other products of the same type design.

``Contacting the Manufacturer'' Paragraph in This Proposed AD

    Since late 2006, we have included a standard paragraph titled
``Airworthy Product'' in all MCAI ADs in which the FAA develops an AD
based on a foreign authority's AD.
    The MCAI or referenced service information in an FAA AD often
directs the owner/operator to contact the manufacturer for corrective
actions, such as a repair. Briefly, the Airworthy Product paragraph
allowed owners/operators to use corrective actions provided by the
manufacturer if those actions were FAA-approved. In addition, the
paragraph stated that any actions approved by the State of Design
Authority (or its delegated agent) are considered to be FAA-approved.
    In an NPRM having Directorate Identifier 2012-NM-101-AD (78 FR
78285, December 26, 2013), we proposed to prevent the use of repairs
that were not specifically developed to correct the unsafe condition,
by requiring that the repair approval provided by the State of Design
Authority or its delegated agent specifically refer to the FAA AD. This
change was intended to clarify the method of compliance and to provide
operators with better visibility of repairs that are specifically
developed and approved to correct the unsafe condition. In addition, we
proposed to change the phrase ``its delegated agent'' to include a
design approval holder (DAH) with State of Design Authority design
organization approval (DOA), as applicable, to refer to a DAH
authorized to approve required repairs for the proposed AD.
    One commenter to the NPRM having Directorate Identifier 2012-NM-
101-AD (78 FR 78285, December 26, 2013) stated the following: ``The
proposed wording, being specific to repairs, eliminates the
interpretation that Airbus messages are acceptable for approving minor
deviations (corrective actions) needed during accomplishment of an AD
mandated Airbus service bulletin.''
    This comment has made the FAA aware that some operators have
misunderstood or misinterpreted the Airworthy Product paragraph to
allow the owner/operator to use messages provided by the manufacturer
as approval of deviations during the accomplishment of an AD-mandated
action. The Airworthy Product paragraph does not approve messages or
other information provided by the manufacturer for deviations to the
requirements of the AD-mandated actions. The Airworthy Product
paragraph only addresses the requirement to contact the manufacturer
for corrective actions for the identified unsafe condition and does not
cover deviations from other AD requirements. However, deviations to AD-
required actions are addressed in 14 CFR 39.17, and anyone may request
the approval for an alternative method of compliance to the AD-required
actions using the procedures found in 14 CFR 39.19.
    To address this misunderstanding and misinterpretation of the
Airworthy Product paragraph, we have changed the paragraph and retitled
it ``Contacting the Manufacturer.'' This paragraph now clarifies that
for any requirement in this proposed AD to obtain corrective actions
from a manufacturer, the actions must be accomplished using a method
approved by the FAA, the Ag[ecirc]ncia Nacional de
Avia[ccedil][atilde]o Civil (ANAC), or ANAC's authorized Designee.
    The Contacting the Manufacturer paragraph also clarifies that, if
approved by the ANAC Designee, the approval must include the Designee's
authorized signature. The Designee signature indicates that the data
and information contained in the document are ANAC-approved, which is
also FAA-approved. Messages and other information provided by the
manufacturer that do not contain the ANAC Designee's authorized
signature approval are not ANAC-approved, unless ANAC directly approves
the manufacturer's message or other information.
    This clarification does not remove flexibility previously afforded
by the Airworthy Product paragraph. Consistent with long-standing FAA
policy, such flexibility was never intended for required actions. This
is also consistent with the recommendation of the Airworthiness
Directive Implementation Aviation Rulemaking Committee to increase
flexibility in complying with ADs by identifying those actions in
manufacturers' service instructions that are ``Required for
Compliance'' with ADs. We continue to work with manufacturers to
implement this recommendation. But once we determine that an action is
required, any deviation from the requirement must be approved as an
alternative method of compliance.

Costs of Compliance

    We estimate that this proposed AD affects 53 airplanes of U.S.
registry.
    We also estimate that it would take about 1 work-hour per product
to comply with the basic requirements of this proposed AD. The average
labor rate is $85 per work-hour. Based on these figures, we estimate
the cost of this proposed AD on U.S. operators to be $4,505, or $85 per
product.

Authority for This Rulemaking

    Title 49 of the United States Code specifies the FAA's authority to
issue rules on aviation safety. Subtitle I, section 106, describes the
authority of the FAA Administrator. ``Subtitle VII: Aviation
Programs,'' describes in more detail the scope of the Agency's
authority.
    We are issuing this rulemaking under the authority described in
``Subtitle VII, Part A, Subpart III, Section 44701: General
requirements.'' Under that section, Congress charges the FAA with
promoting safe flight of civil aircraft in air commerce by prescribing
regulations for practices, methods, and procedures the Administrator
finds necessary for safety in air commerce. This regulation is within
the scope of that authority because it addresses an unsafe condition
that is likely to exist or develop on products identified in this
rulemaking action.

Regulatory Findings

    We determined that this proposed AD would not have federalism
implications under Executive Order 13132. This proposed AD would not
have a substantial direct effect on the States, on the relationship
between the national Government and the States, or on the distribution
of power and responsibilities among the various levels of government.
    For the reasons discussed above, I certify this proposed
regulation:
    1. Is not a ``significant regulatory action'' under Executive Order
12866;
    2. Is not a ``significant rule'' under the DOT Regulatory Policies
and Procedures (44 FR 11034, February 26, 1979);
    3. Will not affect intrastate aviation in Alaska; and
    4. Will not have a significant economic impact, positive or
negative, on a substantial number of small entities under the criteria
of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 39

    Air transportation, Aircraft, Aviation safety, Incorporation by
reference, Safety.

The Proposed Amendment

    Accordingly, under the authority delegated to me by the
Administrator, the FAA proposes to amend 14 CFR part 39 as follows:

PART 39--AIRWORTHINESS DIRECTIVES

0
1. The authority citation for part 39 continues to read as follows:

    Authority: 49 U.S.C. 106(g), 40113, 44701.

Sec.  39.13  [Amended]

0
2. Amend Sec.  39.13 by adding the following new airworthiness
directive (AD):

Empresa Brasileira de Aeronautica S.A. (Embraer): Docket No. FAA-
2014-0586; Directorate Identifier 2013-NM-255-AD.

(a) Comments Due Date

    We must receive comments by October 10, 2014.

(b) Affected ADs

    None.

(c) Applicability

    This AD applies to all Empresa Brasileira de Aeronautica S.A.
(Embraer) Model EMB-135BJ airplanes, certificated in any category.

(d) Subject

    Air Transport Association (ATA) of America Code 28, Fuel; 53,
Fuselage; 54, Nacelles/Pylon.

(e) Reason

    This AD was prompted by a determination that more restrictive
fuel limitations are needed. We are issuing this AD to detect and
correct fatigue cracking of various structural elements and prevent
ignition sources in the fuel system.

(f) Compliance

    Comply with this AD within the compliance times specified,
unless already done.

(g) Maintenance or Inspection Program Revision

    Within 60 days after the effective date of this AD, do the
actions specified in paragraphs (g)(1), (g)(2), and (g)(3) of this
AD.
    (1) Revise the maintenance or inspection program, as applicable,
by incorporating the Critical Design Configuration Control
Limitations (CDCCLs) specified in Embraer Temporary Revision (TR) 8-
1, dated October 26, 2012, to the Embraer Legacy BJ Maintenance
Planning Document (MPG), MPG-1483, into Appendix 2,``Airworthiness
Limitations Requirements,'' of the Embraer Legacy BJ MPG, MPG-1483.
    (2) Revise the maintenance or inspection program, as applicable,
by incorporating the tasks and compliance times specified in Embraer
TR 8-3, dated April 8, 2013, of Embraer Legacy BJ MPG, MPG-1483; and
Embraer TR 8-2, dated December 5, 2012, to the Embraer Legacy BJ
MPG, MPG-1483; into Appendix 2, ``Airworthiness Limitations
Requirements,'' of the Embraer Legacy BJ MPG, MPG-1483. The initial
compliance times for the tasks start at the applicable time
specified in Embraer TR 8-2, dated December 5, 2012, and TR 8-3,
dated April 8, 2013; or within 500 flight cycles after the effective
date of this AD, whichever occurs later. Where Embraer TR 8-2, dated
December 5, 2012, specifies a compliance time in ``flight cycles''
for the pre-mod service bulletin, those compliance times are total
flight cycles.
    (3) Revise the maintenance or inspection program, as applicable,
by incorporating the new fuel system limitations specified in
Embraer TR 8-1, dated October 26, 2012, to the Embraer Legacy BJ
MPG, MPG-1483, into Appendix 2, ``Airworthiness Limitations
Requirements,'' of the Embraer Legacy BJ MPG, MPG-1483. The initial
compliance times for the tasks are specified in paragraphs (g)(3)(i)
and (g)(3)(ii) of this AD.
    (i) For tasks with reference numbers 28-50-01-220-001-A02, 28-
50-08-212-001-A00, 28-50-09-212-001-A00, and 28-50-10-212-001-A00,
at the later of the times specified in paragraph (g)(3)(i)(A) or
(g)(3)(i)(B) of this AD.
    (A) Before the accumulation of 10,000 total flight hours or
within 48 months since the date of issuance of the original
Brazilian standard airworthiness certificate or date of issuance of
the original Brazilian export certificate of airworthiness,
whichever occurs first.
    (B) Within 60 months after the effective date of this AD.
    (ii) For task reference number 28-50-01-720-001-A00, at the
later of the times specified in paragraph (g)(3)(ii)(A) or
(g)(3)(ii)(B) of this AD.
    (A) Before the accumulation of 20,000 total flight hours or
within 96 months since the date of issuance of the original
Brazilian standard airworthiness certificate or date of issuance of
the original Brazilian export certificate of airworthiness,
whichever occurs first.
    (B) Within 60 months after the effective date of this AD.

(h) Incorporation of TRs Into General Revisions

    When the information from Embraer TR 8-1, dated October 26,
2012; TR 8-2, dated December 5, 2012; and TR 8-3, dated April 8,
2013; to the Embraer Legacy BJ MPG, MPG-1483, has been included in
the general revisions of Embraer Legacy BJ MPG, MPG-1483, the
general revisions may be inserted in the MPG, provided that the
relevant information in the general revision is identical to that in
Embraer TR 8-1, dated October 26, 2012; TR 8-2, dated December 5,
2012; and TR 8-3, dated April 8, 2013; and the TRs may be removed.

(i) No Alternative Actions, Intervals, and/or Critical Design
Configuration Control Limitations (CDCCLs)

    After accomplishing the revision required by paragraph (g) of
this AD, no alternative actions (e.g., inspections), intervals, and/
or CDCCLs may be used unless the actions, intervals, and/or CDCCLs
are approved as an alternative method of compliance (AMOC) in
accordance with the procedures specified in paragraph (j) of this
AD.

(j) Other FAA AD Provisions

    The following provisions also apply to this AD:
    (1) Alternative Methods of Compliance (AMOCs): The Manager,
International Branch, ANM-116, Transport Airplane Directorate, FAA,
has the authority to approve AMOCs for this AD, if requested using
the procedures found in 14 CFR 39.19. In accordance with 14 CFR
39.19, send your request to your principal inspector or local Flight
Standards District Office, as appropriate. If sending information
directly to the International Branch, send it to ATTN: Todd
Thompson, Aerospace Engineer, International Branch, ANM-116,
Transport Airplane Directorate, FAA, 1601 Lind Avenue SW., Renton,
WA 98057-3356; telephone<PHONE_NUMBER>; fax<PHONE_NUMBER>. Information
may be emailed to<EMAIL_ADDRESS>Before using any
approved AMOC, notify your appropriate principal inspector, or
lacking a principal inspector, the manager of the local flight
standards district office/certificate holding district office. The
AMOC approval letter must specifically reference this AD.
    (2) Contacting the Manufacturer: For any requirement in this AD
to obtain corrective actions from a manufacturer, the action must be
accomplished using a method approved by the Manager, International
Branch, ANM-116, Transport Airplane Directorate, FAA; or the
Ag[ecirc]ncia Nacional de Avia[ccedil][atilde]o Civil (ANAC); or
ANAC's authorized Designee. If approved by the ANAC Designee, the
approval must include the Designee's authorized signature.

(k) Related Information

    (1) Refer to Mandatory Continuing Airworthiness Information
(MCAI) Brazilian Airworthiness Directive 2013-12-02, effective
December 27, 2013, for related information. This MCAI may be found
in the AD docket on the Internet at http://www.regulations.gov by
searching for and locating Docket No. FAA-2014-0586.
    (2) For service information identified in this AD, contact
Empresa Brasileira de Aeronautica S.A. (Embraer), Technical
Publications Section (PC 060), Av. Brigadeiro Faria Lima, 2170--
Putim--12227-901 S[atilde]o Jose dos Campos--SP--Brasil; telephone
+55 12 3927-5852 or +55 12 3309-0732; fax +55 12 3927-7546; email
<EMAIL_ADDRESS>Internet http://www.flyembraer.com. You may
view this service information at the FAA, Transport Airplane
Directorate, 1601 Lind Avenue SW., Renton, WA. For information on
the availability of this material at the FAA, call<PHONE_NUMBER>.

    Issued in Renton, Washington, on August 15, 2014.
Jeffrey E. Duven,
Manager, Transport Airplane Directorate, Aircraft Certification
Service.
[FR Doc. 2014-20260 Filed 8-25-14; 8:45 am]
BILLING CODE 4910-13-P


[Federal Register Volume 85, Number 42 (Tuesday, March 3, 2020)]
[Notices]
[Pages 12639-12644]
[FR Doc No: 2020-04285]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-88283; File No. SR-CboeBZX-2020-018]

Self-Regulatory Organizations; Cboe BZX Exchange, Inc.; Notice of
Filing and Immediate Effectiveness of a Proposed Rule Change To Allow
the Franklin Liberty International Aggregate Bond Fund To Hold Certain
Instruments in a Manner That May Not Comply With the Generic Listing
Requirements of Rule 14.11(i)

February 26, 2020.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
(``Act''),\1\ and Rule 19b-4 thereunder,\2\ notice is hereby given that
on February 13, 2020, Cboe BZX Exchange, Inc. (``Exchange'') filed with
the Securities and Exchange Commission (``Commission'') the proposed
rule change as described in Items I and II below, which Items have been
prepared by the Exchange. The Commission is publishing this notice to
solicit comments on the proposed rule change from interested persons.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    Cboe BZX Exchange, Inc. (the ``Exchange'' or ``BZX'') is filing
with the Securities and Exchange Commission (``Commission'') a proposed
rule change to allow the Franklin Liberty International Aggregate Bond
Fund (the ``Fund'') of the Franklin Templeton ETF Trust (the ``Trust'')
to hold certain instruments in a manner that may not comply with Rule
14.11(i) (``Managed Fund Shares'').
    The text of the proposed rule change is also available on the
Exchange's website (http://markets.cboe.com/us/equities/regulation/rule_filings/bzx/), at the Exchange's Office of the Secretary, and at
the Commission's Public Reference Room.

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, the Exchange included statements
concerning the purpose of and basis for the proposed rule change and
discussed any comments it received on the proposed rule change. The
text of these statements may be examined at the places specified in
Item IV below. The Exchange has prepared summaries, set

forth in sections A, B, and C below, of the most significant aspects of
such statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

1. Purpose
    The shares of the Fund (the ``Shares'') are currently listed and
traded on the Exchange pursuant to the generic listing standards
applicable to Managed Fund Shares under Rule 14.11(i) (the ``Generic
Listing Standards'') and began trading on June 1, 2018. While the Fund
currently meets all of the Generic Listing Standards, Franklin
Templeton Investment Management Limited, the Fund's investment adviser
(the ``Adviser''), and Franklin Advisers, Inc., the Fund's sub-adviser
(the ``Sub-Adviser'' and collectively with the Adviser, the
``Advisers'') would like to increase the flexibility of the Fund's
holdings in a way that might not meet such requirements. As such, the
Exchange submits this proposal in order to allow the Shares to continue
listing and trading on the Exchange while holding over-the-counter
(``OTC'') Currency Derivatives, as defined below, in a manner that may
not comply with Exchange Rule 14.11(i)(4)(C)(v) \3\ of the Generic
Listing Standards.
---------------------------------------------------------------------------

    \3\ Rule 14.11(i)(4)(C)(v) provides that a fund's portfolio may,
on both an initial and continuing basis, hold OTC derivatives,
including forwards, options, and swaps on commodities, currencies
and financial instruments (e.g., stocks, fixed income, interest
rates, and volatility) or a basket or index of any of the foregoing,
however the aggregate gross notional value of OTC derivatives shall
not exceed 20% of the weight of the portfolio (including gross
notional exposures).
---------------------------------------------------------------------------

    The Shares are offered by the Franklin Templeton ETF Trust, which
was established as a Delaware statutory trust on October 9, 2015.
Franklin Templeton Investment Management Limited acts as adviser to the
Fund. Franklin Advisers, Inc. acts as sub-adviser to the Fund. The
Trust is registered with the Commission as an investment company and
has filed a registration statement on Form N-1A (``Registration
Statement'') with the Commission on behalf of the Fund.\4\
---------------------------------------------------------------------------

    \4\ See Registration Statement for the Trust (File Nos. 333-
208873 and 811-23124). The Exchange notes that the Trust will file a
Form 497 Supplement to its Registration Statement in connection with
the proposed changes contained herein.
---------------------------------------------------------------------------

    Exchange Rule 14.11(i)(7) provides that, if the investment adviser
to the investment company issuing Managed Fund Shares is affiliated
with a broker-dealer, such investment adviser shall erect and maintain
a ``fire wall'' between the investment adviser and the broker-dealer
with respect to access to information concerning the composition and/or
changes to such investment company portfolio.\5\ In addition, Exchange
Rule 14.11(i)(7) further requires that personnel who make decisions on
the investment company's portfolio composition must be subject to
procedures designed to prevent the use and dissemination of material
nonpublic information regarding the applicable investment company
portfolio. The Exchange notes that the Advisers are not registered as
broker-dealers but are affiliated with a broker-dealer and have
implemented and will maintain a fire wall with respect to such broker-
dealer affiliate regarding access to information concerning the
composition and/or changes to the portfolio. In addition, Adviser
personnel who make decisions regarding the Fund's portfolio are subject
to procedures designed to prevent the use and dissemination of material
nonpublic information regarding the Fund's portfolio. In the event that
(a) the Adviser or the Sub-Adviser becomes registered as a broker-
dealer or newly affiliated with a broker-dealer, or (b) any new adviser
or sub-adviser is a registered broker-dealer or becomes affiliated with
a broker-dealer, it will implement and maintain a fire wall with
respect to its relevant personnel or such broker-dealer affiliate, as
applicable, regarding access to information concerning the composition
and/or changes to the portfolio, and will be subject to procedures
designed to prevent the use and dissemination of material non-public
information regarding such portfolio.
---------------------------------------------------------------------------

    \5\ An investment adviser to an open-end fund is required to be
registered under the Investment Advisers Act of 1940 (the ``Advisers
Act''). As a result, the Adviser and its related personnel are
subject to the provisions of Rule 204A-1 under the Advisers Act
relating to codes of ethics. This Rule requires investment advisers
to adopt a code of ethics that reflects the fiduciary nature of the
relationship to clients as well as compliance with other applicable
securities laws. Accordingly, procedures designed to prevent the
communication and misuse of non-public information by an investment
adviser must be consistent with Rule 204A-1 under the Advisers Act.
In addition, Rule 206(4)-7 under the Advisers Act makes it unlawful
for an investment adviser to provide investment advice to clients
unless such investment adviser has (i) adopted and implemented
written policies and procedures reasonably designed to prevent
violation, by the investment adviser and its supervised persons, of
the Advisers Act and the Commission rules adopted thereunder; (ii)
implemented, at a minimum, an annual review regarding the adequacy
of the policies and procedures established pursuant to subparagraph
(i) above and the effectiveness of their implementation; and (iii)
designated an individual (who is a supervised person) responsible
for administering the policies and procedures adopted under
subparagraph (i) above.
---------------------------------------------------------------------------

    The Fund intends to qualify each year as a regulated investment
company under Subchapter M of the Internal Revenue Code of 1986, as
amended.
    While the Fund seeks to hold both exchange-listed derivatives and
OTC derivatives, it does not seek an exemption for its holdings in
exchange-listed derivatives under Rule 14.11(i)(4)(C)(iv).
Specifically, the Exchange submits this proposal in order to allow the
Fund to hold only OTC Currency Derivatives, as defined below, in a
manner that does not comply with Exchange Rule 14.11(i)(4)(C)(v).\6\
Otherwise, the Fund will comply with all other listing requirements on
an initial and continued listing basis under the Generic Listings
Standards.
---------------------------------------------------------------------------

    \6\ In particular, the Fund may not meet the requirement under
Exchange Rule 14.11(i)(4)(C)(v) that the aggregate gross notional
value of OTC currency derivatives shall not exceed 20% of the weight
of the portfolio (including gross notional exposures).
---------------------------------------------------------------------------

Franklin Liberty International Aggregate Bond Fund
    As set forth in the Registration Statement, the Fund is an actively
managed exchange-traded fund that will seek total investment return
consisting of a combination of interest income and capital
appreciation. When choosing investments for the Fund, the Advisers
allocate the Fund's assets based upon their assessment of changing
market, political and economic conditions. The Advisers consider
various factors, including evaluation of interest rates, currency
exchange rate changes and credit risks.
    The Fund seeks to achieve its investment objective by investing,
under Normal Market Conditions,\7\ at least 80% of its net assets in
bonds \8\ and investments that provide exposure to bonds.\9\ The Fund
invests predominantly in fixed and floating-rate

bonds issued by governments, government agencies and governmental-
related or corporate issuers located outside the U.S. The Fund may also
invest in securities or structured products that are linked to or
derive their value from another security, asset or currency of any
nation. The Fund may invest in debt securities of any maturity or
duration. Although the Fund may buy bonds rated in any category,
including securities in default, it focuses on ``investment grade''
bonds.\10\ The Fund may only invest up to 20% of its total assets in
bonds that are rated below investment grade or, if unrated, determined
by the Advisers to be of comparable quality.
---------------------------------------------------------------------------

    \7\ The term ``Normal Market Conditions'' includes, but is not
limited to, the absence of trading halts in the applicable financial
markets generally; operational issues causing dissemination of
inaccurate market information or system failures; or force majeure
type events such as natural or man-made disaster, act of God, armed
conflict, act of terrorism, riot or labor disruption, or any similar
intervening circumstance. In response to adverse market, economic,
political, or other conditions, the Fund reserves the right to
invest in U.S. government securities, other money market instruments
(as defined below), and cash, without limitation, as determined by
the Advisers. In the event the Fund engages in these temporary
defensive strategies that are inconsistent with its investment
strategies, the Fund's ability to achieve its investment objectives
may be limited.
    \8\ For purposes of this proposal, the term ``bonds'' include
debt obligations of any maturity, such as bonds, notes, bills and
debentures.
    \9\ As noted in the Fund's prospectus, derivatives that provide
exposure to bonds may be used to satisfy the Fund's 80% policy.
    \10\ ``Investment grade'' bonds refer to issues rated in the top
four rating categories at the time of purchase by at least one
independent rating agency, such as Standard & Poor's (S&P[supreg])
or Moody's Investors Service (Moody's) or, if unrated, determined by
the Fund's Advisers to be of comparable quality.
---------------------------------------------------------------------------

    Currently, under Normal Market Conditions, the Fund holds only the
following instruments:
     Fixed income instruments; \11\
---------------------------------------------------------------------------

    \11\ As provided in Rule 14.11(i)(4)(C)(ii), the term ``fixed
income'' securities are debt securities that are notes, bonds,
debentures, or evidence of indebtedness that include, but are not
limited to, U.S. Department of Treasury securities (``Treasury
Securities''), government-sponsored entity securities (``GSE
Securities''), municipal securities, trust preferred securities,
supranational debt and debt of a foreign country or a subdivision
thereof, investment grade and high yield corporate debt, bank loans,
mortgage and asset backed securities, and commercial paper. To the
extent that a portfolio includes convertible securities, the fixed
income security into which such security is converted shall meet the
criteria of Rule 14.11(i)(4)(C)(ii) after converting.
---------------------------------------------------------------------------

     Cash and Cash Equivalents; \12\
---------------------------------------------------------------------------

    \12\ As defined in Exchange Rule 14.11(i)(4)(C)(iii)(b), Cash
Equivalents are short-term instruments with maturities of less than
three months, which includes only the following: (i) U.S. Government
securities, including bills, notes, and bonds differing as to
maturity and rates of interest, which are either issued or
guaranteed by the U.S. Treasury or by U.S. Government agencies or
instrumentalities; (ii) certificates of deposit issued against funds
deposited in a bank or savings and loan association; (iii) bankers
acceptances, which are short-term credit instruments used to finance
commercial transactions; (iv) repurchase agreements and reverse
repurchase agreements; (v) bank time deposits, which are monies kept
on deposit with banks or savings and loan associations for a stated
period of time at a fixed rate of interest; (vi) commercial paper,
which are short-term unsecured promissory notes; and (vii) money
market funds.
---------------------------------------------------------------------------

     Exchange-listed currency futures;
     Interest rate/bond futures;
     Equity securities and investments including convertible
securities, preferred stock, warrants, and rights;
     Depository receipts;
     Securities of other investment companies, including ETFs;
     Deliverable currency forwards;
     Non-deliverable currency forwards; and
     OTC interest rate swap agreements.
    As stated previously, the Fund's holdings set forth above meet all
of the generic listing standards of rule 14.11(i)(4)(C)(v). Thus, the
OTC interest rate swap agreements noted above will not exceed 20% of
the weight of the portfolio (including gross notional exposures).
    However, the Advisers now seek to manage the Fund's currency risk
by hedging substantially all of the Fund's foreign currency exposure in
its portfolio (the ``Currency Hedge''), up to a 100% hedge.\13\ Under
Normal Market Conditions,\14\ the Fund will primarily achieve the
Currency Hedge by using OTC deliverable and non-deliverable currency
forwards and exchange-listed currency futures. In certain conditions,
the Fund may also achieve the Currency Hedge by using exchange-listed
currency options, including exchange-listed and OTC options on currency
futures, OTC synthetic non-deliverable currency forwards, currency
swaps, and OTC currency options (collectively, with OTC deliverable and
non-deliverable currency forwards and exchange-listed currency futures,
referred to as the ``Currency Derivatives'').
---------------------------------------------------------------------------

    \13\ The Fund expects to primarily invest its net assets in
fixed and floating-rate bonds issued by governments, government
agencies and governmental-related or corporate issuers located
outside the U.S. The Fund expects that the gross notional value of
the Currency Hedge would be equal to the value of the unhedged
currency exposure associated with its primary holdings, which would
be approximately 50% of the weight of the portfolio (including gross
notional exposures).
    \14\ See Exchange Rule 14.11(i)(3)(E).
---------------------------------------------------------------------------

    As noted above, all of the Fund's holdings will meet the Generic
Listing Standards with the exception of its holdings in OTC Currency
Derivatives, which may not meet the requirement under Rule
14.11(i)(4)(C)(v) that prevents the aggregate gross notional value of
OTC derivatives from exceeding 20% of the weight of the portfolio
(including gross notional exposures).
Precedent and Policy Discussion
    As described above, the Fund will meet all of the Generic Listing
Standards except as it may relate to its holdings in OTC Currency
Derivatives, which will be used, in conjunction with its holdings in
exchange-listed Currency Derivatives, to achieve its Currency
Hedge.\15\ The Exchange believes that this proposal does not raise any
substantive issues for the Commission to review because there are
numerous instances in which the Commission has approved the listing and
trading of series of Managed Fund Shares that employ substantially
similar hedging strategies,\16\ especially when compared to the Hedged
ADR Approval Order. Specifically, the Hedged ADR Approval Order
approved the listing and trading of eighteen series of Managed Fund
Shares (the ``Hedged ADR Funds''), each of which consisted of only two
components: (i) A single ADR; and (ii) OTC currency swaps used to hedge
against fluctuations in the exchange rate between the U.S. dollar and
the local currency of the foreign security underlying the ADR. In
addition to not meeting Rule 14.11(i)(4)(C)(v) related to the OTC
derivatives used to hedge currency exposure, each series of the Hedged
ADR Funds also did not meet the concentration \17\ and diversity \18\
requirements related to their respective equity holdings. Stated
another way, the Fund is proposing to implement a Currency Hedge using
similar instruments as the Hedged ADR Funds, but does not require the
additional relief from the fixed income concentration \19\ and
diversity \20\ requirements holdings portion of the Generic Listing
Standards that was necessary (as it pertained to equity holdings) for
the Hedged ADR Funds to list and trade. While the Fund intends to use
primarily OTC deliverable and non-deliverable currency forwards and
exchange-listed currency futures to hedge its currency

risk rather than currency swaps, the policy concerns surrounding the
fact that the Fund will not meet Rule 14.11(i)(4)(C)(v) are the same,
and those concerns are mitigated for the same reasons, as discussed
below.
---------------------------------------------------------------------------

    \15\ The Exchange notes that the Fund's holdings in exchange-
listed derivatives will meet the requirements set forth in Exchange
Rule 14.11(i)(4)(C)(iv).
    \16\ See Securities Exchange Act Release Nos. 84143 (September
14, 2018), 83 FR 47659 (September 20, 2018) (SR-CboeBZX-2018-019)
(order approving the listing and trading of eighteen series of
Managed Fund Shares that allowed each series to hedge its foreign
equity position with up to 50% gross notional exposure to OTC
currency swaps) (the ``Hedged ADR Approval Order''); 85474 (March
29, 2019), 84 FR 13371 (April 4, 2019) (SR-CboeBZX-2019-019); 84818
(December 13, 2018), 83 FR 65189 (December 19, 2018) (SR-NYSEArca-
2018-75) (order approving the listing and trading of a series of
Managed Fund Shares that may hold up to 50% of the aggregate gross
notional value of the fund's portfolio in OTC derivatives for the
purpose of reducing currency, interest rate, credit, or duration
risk, in addition to allowing the fund to hold an additional 20% of
non-hedging OTC derivatives); 82591 (January 26, 2018) 83 FR 4707
(February 1, 2018) (SR-BatsBZX-2017-54) (the ``Inflation Hedged
Fund'') (order approving the listing and trading of a series of
Managed Fund Shares that could gain up to 50% gross notional
exposure to OTC derivatives in order to hedge against inflation in
the fund's portfolio); and 83363 (June 1, 2018), 83 FR 26531 (June
7, 2018) (SR-CboeBZX-2018-036) (notice of filing and immediate
effectiveness of a proposal to allow the Inflation Hedged Fund to
increase its potential exposure to OTC derivative instruments from
50% to 60% of the fund's gross notional value).
    \17\ See Rule 14.11(i)(4)(C)(i)(a)(3).
    \18\ See Rule 14.11(i)(4)(C)(i)(a)(4).
    \19\ See Rule 14.11(i)(4)(C)(ii)(c).
    \20\ See Rule 14.11(i)(4)(C)(ii)(d).
---------------------------------------------------------------------------

    The Exchange believes that, while the portfolio of the Fund might
not meet Rule 14.11(i)(4)(C)(v), the policy issues that the rule is
intended to address are otherwise mitigated by the structure and
purpose of the Currency Hedge within the Fund.\21\ Specifically, the
Exchange believes that the policy issues that Rule 14.11(i)(4)(C)(v) is
intended to address are mitigated by the way that the Fund will use OTC
Currency Derivatives. The rule is intended to mitigate concerns around
the manipulability of a particular underlying reference asset or
derivatives contract. While the Currency Hedge positions taken by the
Fund may not meet the Generic Listing Standards related to OTC
derivatives holdings, the policy concerns about limiting exposure to
potentially manipulable underlying reference assets that the Generic
Listing Standards are intended to address are otherwise mitigated by
the liquidity in the underlying spot currency market that prevents
manipulation of the reference prices used by the Currency Hedge.\22\
The Fund will attempt to limit counterparty risk in OTC derivatives by:
(i) Entering into such contracts only with counterparties the Advisers
believe are creditworthy; (ii) limiting the Fund's exposure to each
counterparty; and (iii) monitoring the creditworthiness of each
counterparty and the Fund's exposure to each counterparty on an ongoing
basis.
---------------------------------------------------------------------------

    \21\ As described above, the Fund expects to invest in excess of
80% of its net assets in bonds and investments that provide exposure
to bonds in a manner that will comply with the Generic Listing
Standards.
    \22\ Based on statistics reported by the Bank for International
Settlements, there is significant liquidity in the spot market. See
``Turnover of OTC foreign exchange instruments, by currency''
available at: https://stats.bis.org/statx/srs/table/d11.3.
---------------------------------------------------------------------------

Availability of Information
    As noted above, the Fund will each comply with the requirements for
Managed Fund Shares related to Disclosed Portfolio, Net Asset Value,
and the Intraday Indicative Value. Additionally, the intra-day, closing
and settlement prices of the component fixed income securities will be
readily available from the securities exchanges on which such
securities are traded, as well as published or other public sources, or
online information services such as Bloomberg or Reuters. Intraday
price quotations on the OTC Currency Derivatives are available from
major broker-dealer firms and from third-parties, which may provide
prices free with a time delay or in real-time for a paid fee. Price
information for cash equivalents will be available from major market
data vendors. The Fund's Disclosed Portfolio will be available on the
issuer's website (https://www.franklintempleton.com/) free of charge.
The Fund's website will include the prospectus and additional
information related to NAV and other applicable quantitative
information. Information regarding market price and trading volume of
the Shares will be continuously available throughout the day on
brokers' computer screens and other electronic services. Information
regarding the previous day's closing price and trading volume for the
Shares will be published daily in the financial section of newspapers.
Trading in the Shares may be halted for market conditions or for
reasons that, in the view of the Exchange, make trading inadvisable.
The Exchange deems the Shares to be equity securities, thus rendering
trading in the Shares subject to the Exchange's existing rules
governing the trading of equity securities. The Exchange has
appropriate rules to facilitate trading in the shares during all
trading sessions.
Surveillance
    The Exchange believes that its surveillance procedures are adequate
to properly monitor the trading of the Fund on the Exchange during all
trading sessions and to deter and detect violations of Exchange rules
and the applicable federal securities laws. Trading of the Fund through
the Exchange will continue to be subject to the Exchange's surveillance
procedures for derivative products, including Managed Fund Shares. The
issuer has represented to the Exchange that it will advise the Exchange
of any failure by the Fund to comply with the continued listing
requirements, and, pursuant to its obligations under Section 19(g)(1)
of the Act, the Exchange will surveil for compliance with the continued
listing requirements. If the Fund is not in compliance with the
applicable listing requirements, the Exchange will commence delisting
proceedings under Rule 14.12. The Exchange may obtain information
regarding trading in the Fund via the ISG, from other exchanges that
are members or affiliates of the ISG, or with which the Exchange has
entered into a comprehensive surveillance sharing agreement.
Additionally, the Exchange or FINRA, on behalf of the Exchange, are
able to access, as needed, trade information for certain fixed income
instruments reported to TRACE.
2. Statutory Basis
    The Exchange believes that the proposal is consistent with Section
6(b) of the Act \23\ in general and Section 6(b)(5) of the Act \24\ in
particular in that it is designed to prevent fraudulent and
manipulative acts and practices, to promote just and equitable
principles of trade, to foster cooperation and coordination with
persons engaged in facilitating transactions in securities, to remove
impediments to and perfect the mechanism of a free and open market and
a national market system and, in general, to protect investors and the
public interest. Specifically, the Exchange believes that the proposal
is consistent with Rule 6(b)(5) of the Act in that is designed to
prevent fraudulent and manipulative acts and practices because the
policy concerns about limiting exposure to potentially manipulable
underlying reference assets that the Generic Listing Standards are
intended to address, specifically Rule 14.11(i)(4)(C)(v) related to OTC
holdings, are otherwise mitigated by the liquidity in the underlying
spot currency market that prevents manipulation of the reference prices
used by the Currency Hedge. Specifically, the Exchange believes that
the policy issues that Rule 14.11(i)(4)(C)(v) is intended to address
are mitigated by the way that the Fund will use OTC Currency
Derivatives. The rule is intended to mitigate concerns around the
manipulability of a particular underlying reference asset or
derivatives contract. As noted above, while the Currency Hedge
positions that might be taken by the Fund may not meet the Generic
Listing Standards related to OTC derivatives holdings, the policy
concerns about limiting exposure to potentially manipulable underlying
reference assets that the Generic Listing Standards are intended to
address are otherwise mitigated by the liquidity in the underlying spot
currency market that prevents manipulation of the reference prices used
by the Currency Hedge. The Fund will attempt to limit counterparty risk
in OTC derivatives by: (i) Entering into such contracts only with
counterparties the Advisers believe are creditworthy; (ii) limiting the
Fund's exposure to each counterparty; and (iii) monitoring the
creditworthiness of each counterparty and the Fund's exposure to each
counterparty on an ongoing basis.
---------------------------------------------------------------------------

    \23\ 15 U.S.C. 78f.
    \24\ 15 U.S.C. 78f(b)(5).
---------------------------------------------------------------------------

    The Exchange also notes that there are numerous instances in which
the Commission has approved the listing and trading of series of
Managed Fund

Shares that employ nearly identical or substantially similar hedging
strategies.\25\ Specifically, the Hedged ADR Approval Order approved
the listing and trading the Hedged ADR Funds, each of which consisted
of only two components: (i) A single ADR; and (ii) OTC currency swaps
used to hedge against fluctuations in the exchange rate between the
U.S. dollar and the local currency of the foreign security underlying
the ADR. In addition to not meeting Rule 14.11(i)(4)(C)(v) related to
the OTC currency swaps used to hedge currency exposure, each series of
the Hedged ADR Funds also did not meet the concentration \26\ and
diversity \27\ requirements related to their respective equity
holdings. Stated another way, the Fund is proposing to implement a
Currency Hedge using similar instruments as the Hedged ADR Funds, but
do not require the additional relief from the fixed income
concentration \28\ and diversity \29\ requirements holdings portion of
the Generic Listing Standards that was necessary (as it pertained to
equity holdings) for the Hedged ADR Funds to list and trade.
---------------------------------------------------------------------------

    \25\ See Securities Exchange Act Release Nos. 84143 (September
14, 2018), 83 FR 47659 (September 20, 2018) (SR-CboeBZX-2018-019)
(order approving the listing and trading of eighteen series of
Managed Fund Shares that allowed each series to hedge its foreign
equity position with up to 50% gross notional exposure to OTC
currency swaps) (the ``Hedged ADR Approval Order''); 84818 (December
13, 2018), 83 FR 65189 (December 19, 2018) (SR-NYSEArca-2018-75)
(order approving the listing and trading of a series of Managed Fund
Shares that may hold up to 50% of the aggregate gross notional value
of the fund's portfolio in OTC derivatives for the purpose of
reducing currency, interest rate, credit, or duration risk, in
addition to allowing the fund to hold an additional 20% of non-
hedging OTC derivatives); 82591 (January 26, 2018) 83 FR 4707
(February 1, 2018) (SR-BatsBZX-2017-54) (the ``Inflation Hedged
Fund'') (order approving the listing and trading of a series of
Managed Fund Shares that could gain up to 50% gross notional
exposure to OTC derivatives in order to hedge against inflation in
the fund's portfolio); and 83363 (June 1, 2018), 83 FR 26531 (June
7, 2018) (SR-CboeBZX-2018-036) (notice of filing and immediate
effectiveness of a proposal to allow the Inflation Hedged Fund to
move increase its potential exposure to OTC derivative instruments
from 50% to 60% of the fund's gross notional value).
    \26\ See Rule 14.11(i)(4)(C)(i)(a)(3).
    \27\ See Rule 14.11(i)(4)(C)(i)(a)(4).
    \28\ See Rule 14.11(i)(4)(C)(ii)(c).
    \29\ See Rule 14.11(i)(4)(C)(ii)(d).
---------------------------------------------------------------------------

    The Exchange believes that its surveillance procedures are adequate
to properly monitor the trading of the Fund on the Exchange during all
trading sessions and to deter and detect violations of Exchange rules
and the applicable federal securities laws. Trading of the Fund through
the Exchange will be subject to the Exchange's surveillance procedures
for derivative products, including Managed Fund Shares. All statements
and representations made in this filing regarding the description of
the portfolio or reference assets, limitations on portfolio holdings or
reference assets, dissemination and availability of reference assets
and intraday indicative values, and the applicability of Exchange
listing rules specified in this filing shall constitute continued
listing requirements for the Fund. The Trust, on behalf of the Fund,
has represented to the Exchange that it will advise the Exchange of any
failure by the Fund or the Shares to comply with the continued listing
requirements, and, pursuant to its obligations under Section 19(g)(1)
of the Act, the Exchange will surveil for compliance with the continued
listing requirements. If the Fund or the Shares are not in compliance
with the applicable listing requirements, the Exchange will commence
delisting procedures under Exchange Rule 14.12.
    As described above, the Exchange may obtain information regarding
trading in the Fund via the ISG, from other exchanges that are members
or affiliates of the ISG, or with which the Exchange has entered into a
comprehensive surveillance sharing agreement. Additionally, the
Exchange or FINRA, on behalf of the Exchange, are able to access, as
needed, trade information for certain fixed income instruments reported
to TRACE.
    For the above reasons, the Exchange believes that the proposed rule
change is consistent with the requirements of Section 6(b)(5) of the
Act.

B. Self-Regulatory Organization's Statement on Burden on Competition

    The Exchange does not believe that the proposed rule change will
impose any burden on competition that is not necessary or appropriate
in furtherance of the purpose of the Act. The Exchange notes that the
proposed rule change will facilitate the listing and trading of
additional series of Managed Fund Shares that will enhance competition
among market participants, to the benefit of investors and the
marketplace.

C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Change Received From Members, Participants, or Others

    The Exchange has neither solicited nor received written comments on
the proposed rule change.

III. Date of Effectiveness of the Proposed Rule Change and Timing for
Commission Action

    The Exchange has filed the proposed rule change pursuant to Section
19(b)(3)(A)(iii) of the Act \30\ and Rule 19b-4(f)(6) thereunder.\31\
Because the proposed rule change does not: (i) Significantly affect the
protection of investors or the public interest; (ii) impose any
significant burden on competition; and (iii) become operative for 30
days from the date on which it was filed, or such shorter time as the
Commission may designate, if consistent with the protection of
investors and the public interest, the proposed rule change has become
effective pursuant to Section 19(b)(3)(A) of the Act \32\ and Rule 19b-
4(f)(6) thereunder.\33\
---------------------------------------------------------------------------

    \30\ 15 U.S.C. 78s(b)(3)(A)(iii).
    \31\ 17 CFR 240.19b-4(f)(6).
    \32\ 15 U.S.C. 78s(b)(3)(A).
    \33\ 17 CFR 240.19b-4(f)(6). In addition, Rule 19b-4(f)(6)(iii)
requires the Exchange to give the Commission written notice of the
Exchange's intent to file the proposed rule change, along with a
brief description and text of the proposed rule change, at least
five business days prior to the date of filing of the proposed rule
change, or such shorter time as designated by the Commission. The
Exchange has satisfied this requirement.
---------------------------------------------------------------------------

    A proposed rule change filed under Rule 19b-4(f)(6) \34\ normally
does not become operative for 30 days after the date of the filing.
However, pursuant to Rule 19b-4(f)(6)(iii),\35\ the Commission may
designate a shorter time if such action is consistent with the
protection of investors and the public interest. The Exchange has asked
the Commission to waive the 30-day operative delay to allow the Fund to
fully implement its Currency Hedge without unnecessary delay. The
Exchange states that the Fund is proposing to implement a Currency
Hedge using similar instruments as the Hedged ADR Funds, and that
waiver of the 30-day operative delay would more quickly facilitate the
Advisers' ability to fully implement its Currency Hedge, which would
enhance competition among market participants to the benefit of
investors and the marketplace. The Commission believes that the
proposal raises no substantive issues and that therefore waiver of the
30-day operative delay is consistent with the protection of investors
and the public interest. Accordingly, the Commission hereby waives the
30-day operative delay and designates the proposed rule change
operative upon filing.\36\
---------------------------------------------------------------------------

    \34\ 17 CFR 240.19b-4(f)(6).
    \35\ 17 CFR 240.19b-4(f)(6)(iii).
    \36\ For purposes only of waiving the operative delay, the
Commission has considered the proposed rule's impact on efficiency,
competition, and capital formation. See 15 U.S.C. 78c(f).
---------------------------------------------------------------------------

    At any time within 60 days of the filing of the proposed rule
change, the Commission summarily may temporarily suspend such rule
change if it appears to the Commission that such

action is necessary or appropriate in the public interest, for the
protection of investors, or otherwise in furtherance of the purposes of
the Act. If the Commission takes such action, the Commission shall
institute proceedings to determine whether the proposed rule change
should be approved or disapproved.

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views, and
arguments concerning the foregoing, including whether the proposed rule
change is consistent with the Act. Comments may be submitted by any of
the following methods:

Electronic Comments

     Use the Commission's internet comment form (http://www.sec.gov/rules/sro.shtml); or
     Send an email to<EMAIL_ADDRESS>Please include
File Number SR-CboeBZX-2020-018 on the subject line.

Paper Comments

     Send paper comments in triplicate to Secretary, Securities
and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.

All submissions should refer to File Number SR-CboeBZX-2020-018. This
file number should be included on the subject line if email is used. To
help the Commission process and review your comments more efficiently,
please use only one method. The Commission will post all comments on
the Commission's internet website (http://www.sec.gov/rules/sro.shtml).
Copies of the submission, all subsequent amendments, all written
statements with respect to the proposed rule change that are filed with
the Commission, and all written communications relating to the proposed
rule change between the Commission and any person, other than those
that may be withheld from the public in accordance with the provisions
of 5 U.S.C. 552, will be available for website viewing and printing in
the Commission's Public Reference Room, 100 F Street NE, Washington, DC
20549, on official business days between the hours of 10:00 a.m. and
3:00 p.m. Copies of the filing also will be available for inspection
and copying at the principal office of the Exchange. All comments
received will be posted without change. Persons submitting comments are
cautioned that we do not redact or edit personal identifying
information from comment submissions. You should submit only
information that you wish to make available publicly. All submissions
should refer to File Number SR-CboeBZX-2020-018, and should be
submitted on or before March 24, 2020.

    For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\37\
---------------------------------------------------------------------------

    \37\ 17 CFR 200.30-3(a)(12)
---------------------------------------------------------------------------

J. Matthew DeLesDernier,
Assistant Secretary.
[FR Doc. 2020-04285 Filed 3-2-20; 8:45 am]
 BILLING CODE 8011-01-P